CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Décembre 2023 - 2:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
Sean McCarthy, D.Phil., president, chief executive officer, and
chairman, will present at the 42nd Annual J.P. Morgan Healthcare
Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT.
A live webcast of the presentation will be available on the
Events and Presentations page of CytomX’s website at
www.cytomx.com. An archived replay will be available for 30 days
following the event. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conference.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics designed to
be localized to the tumor microenvironment. By pioneering a novel
pipeline of localized biologics, powered by its Probody® technology
platform, CytomX’s goal is to transcend the limits of current
cancer treatments. CytomX’s robust and differentiated pipeline
comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engaging bispecific antibodies, and immune modulators such as
cytokines and checkpoint inhibitors. CytomX’s clinical pipeline
includes the cancer immunotherapeutic candidates CX-904 and
BMS-986288. CX-904, partnered with Amgen, is a conditionally
activated T-cell-engaging bispecific antibody targeting the
epidermal growth factor receptor (EGFR) on tumor cells and the CD3
receptor on T cells. BMS-986288, partnered with Bristol Myers
Squibb, is a conditionally activated CTLA-4-targeting antibody that
is a non-fucosylated version of ipilimumab. In addition, CytomX has
a diverse, emerging portfolio of wholly-owned drug candidates
including CX-2051, a conditionally activated ADC directed toward
epithelial cell adhesion molecule, EpCAM, with potential
applicability across multiple EpCAM-expressing epithelial cancers,
and CX-801, an interferon alpha-2b Probody cytokine that has broad
potential applicability in traditionally immuno-oncology sensitive
as well as insensitive (cold) tumors. CytomX has established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
Investor Contact:Chris
OgdenSVP, Finance and Accounting cogden@cytomx.com(317)
767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
CytomX Therapeutics (NASDAQ:CTMX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024